重组人血管内皮抑制素联合同步放化疗治疗鼻咽癌的疗效观察

Influence of recombinant human endostatin combined concurrent chemoradiotherapy on prognosis and malignant degree of nasopharyngeal carcinoma

摘要:

摘要：目的  分析重组人血管内皮抑制素联合同步放化疗对鼻咽癌患者预后和肿瘤恶性程度的影响。方法  选取2012年11月-2015年1月在该院接受治疗的78例鼻咽癌患者作为研究对象，根据治疗方式分为接受重组人血管内皮抑制素联合同步放化疗的观察组36例，接受单纯同步放化疗的对照组42例。对比两组患者治疗后鼻咽癌预后相关因子蛋白表达量、血清生长因子水平、血清病情相关因子水平差异。结果  观察组患者治疗后鼻咽癌标本中乙酰肝素酶、蛋白激酶CK2β、缺氧诱导因子-1α、潜伏膜蛋白蛋白表达量均低于对照组（P <0.05）；观察组患者治疗后血清转化生长因子β1、血小板源性生长因子-β、表皮生长因子、表皮生长因子受体、血管内皮生长因子值均低于对照组（P <0.05）；观察组患者治疗后血清巨噬细胞炎性蛋白-3α、α-羟基丁酸脱氢酶、细胞角蛋白19片段、胸苷激酶-1、Ⅲ型前胶原、层粘连蛋白值均低于对照组（P <0.05）。结论  鼻咽癌患者接受重组人血管内皮抑制素联合同步放化疗，可以降低肿瘤恶性程度并优化治疗预后，具有积极的临床意义。

Abstract:

Abstract: Objective To analyze the influence of recombinant human endostatin combined concurrent chemoradiotherapy on prognosis and malignant degree of nasopharyngeal carcinoma. Methods Seventy-eight cases of nasopharyngeal carcinoma patients in our hospital between November 2012 and January 2015 were chosen as research subjects and divided into observation group (36 cases, received recombinant human Endostatin combined concurrent chemoradiotherapy) and control group (42 cases, received chemoradiotherapy alone). Nasopharyngeal carcinoma prognostic factor protein expression and serum growth factor level and serum disease-associated factor levels were compared between the two groups. Results The expression levels of heparitinase (HPA), CK2β, HIF-1α and LMP1 protein in the nasopharyngeal carcinoma specimens of the observation group were lower than those of the control group after treatment (P < 0.05). Serum TGF-β1, PDGF-β, EGF, EGFR and VEGF values in the observation group were lower than those in the control group after treatment (P < 0.05). Serum MTP-3α, α-HBDH, CYFRA21-1, TK1, PCⅢ and LN values in the observation group were lower than those in the control group (P < 0.05). Conclusions Recombinant human endostatin combined concurrent chemoradiotherapy can reduce degree of malignancy and improve prognosis in nasopharyngeal carcinoma patients, and has positive significance.